$ 28.2
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of VERA is 64 and suggests 128% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
